ES2116918A1 - Medicamento para la administracion nasal. - Google Patents

Medicamento para la administracion nasal.

Info

Publication number
ES2116918A1
ES2116918A1 ES09601391A ES9601391A ES2116918A1 ES 2116918 A1 ES2116918 A1 ES 2116918A1 ES 09601391 A ES09601391 A ES 09601391A ES 9601391 A ES9601391 A ES 9601391A ES 2116918 A1 ES2116918 A1 ES 2116918A1
Authority
ES
Spain
Prior art keywords
nasal administration
medicaments
vaccine
medicament
particle size
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
ES09601391A
Other languages
English (en)
Other versions
ES2116918B1 (es
Inventor
Yutaka Mizushima
Yasuo Kosaka
Kayoko Hosakawa
Ryozo Nagata
Megumu Higaki
Rie Igarashi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
LTT Institute Co Ltd
Original Assignee
LTT Institute Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by LTT Institute Co Ltd filed Critical LTT Institute Co Ltd
Publication of ES2116918A1 publication Critical patent/ES2116918A1/es
Application granted granted Critical
Publication of ES2116918B1 publication Critical patent/ES2116918B1/es
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Reproductive Health (AREA)
  • Otolaryngology (AREA)
  • Diabetes (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

MEDICAMENTO PARA LA ADMINISTRACION NASAL. COMPRENDE UNA VACUNA O UN PEPTIDO FARMACOLOGICAMENTE ACTIVO COMBINADOS CON UN POLVO DE RESINA DE INTERCAMBIO DE IONES CUYO TAMAÑO MEDIO DE PARTICULA NO ES MAYOR DE 200 UM. APLICABLE A LA PREVENCION Y AL TRATAMIENTO DE ENFERMEDADES.
ES09601391A 1995-07-12 1996-06-21 Medicamento para la administracion nasal. Expired - Fee Related ES2116918B1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP07197919A JP3098401B2 (ja) 1995-07-12 1995-07-12 経鼻投与用製剤

Publications (2)

Publication Number Publication Date
ES2116918A1 true ES2116918A1 (es) 1998-07-16
ES2116918B1 ES2116918B1 (es) 1999-04-01

Family

ID=16382464

Family Applications (1)

Application Number Title Priority Date Filing Date
ES09601391A Expired - Fee Related ES2116918B1 (es) 1995-07-12 1996-06-21 Medicamento para la administracion nasal.

Country Status (11)

Country Link
US (1) US5942242A (es)
JP (1) JP3098401B2 (es)
KR (1) KR970005305A (es)
CN (1) CN1140609A (es)
AU (1) AU702108B2 (es)
CA (1) CA2180215A1 (es)
DE (1) DE19627392A1 (es)
ES (1) ES2116918B1 (es)
FR (1) FR2736547A1 (es)
GB (1) GB2303064B (es)
IT (1) IT1284049B1 (es)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2126536A1 (es) * 1996-10-07 1999-03-16 Fuji Yakuhin Kogyo Kk "preparado farmaceutico para administracion intranasal"y procedimiento para su produccion.

Families Citing this family (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CU22629A1 (es) * 1997-03-06 2000-12-22 Ct Ingenieria Genetica Biotech Formulaciones inmunopotenciadoras para uso vacunal
WO1998058654A1 (fr) * 1997-06-20 1998-12-30 Ohkura Pharmaceutical Co., Ltd. Composition sous forme de gel
TWI243687B (en) 1998-04-21 2005-11-21 Teijin Ltd Pharmaceutical composition for application to mucosa
US7022683B1 (en) 1998-05-13 2006-04-04 Carrington Laboratories, Inc. Pharmacological compositions comprising pectins having high molecular weights and low degrees of methoxylation
DE19826628C1 (de) * 1998-06-17 2000-07-20 Werner Kern Intranasale Verwendung von Insulin bei Hirnleistungsstörungen
US9006175B2 (en) 1999-06-29 2015-04-14 Mannkind Corporation Potentiation of glucose elimination
AR026073A1 (es) 1999-10-20 2002-12-26 Nycomed Gmbh Composicion farmaceutica acuosa que contiene ciclesonida
US6894026B1 (en) * 2000-01-11 2005-05-17 Atossa Healthcare, Inc. Long-acting oxytocin analogues for the treatment and prevention of breast cancer and psychiatric disorders
US6651655B1 (en) * 2000-01-18 2003-11-25 Quadrant Technologies Limited Inhaled vaccines
MXPA02007052A (es) * 2000-01-20 2002-12-13 Basilea Pharmaceutica Ag Composiciones que se administran nasalmente y que contienen peptidos ciclicos.
EP1398038B2 (en) * 2000-02-08 2011-01-26 Allergan, Inc. Botulinum toxin pharmaceutical compositions
US7780967B2 (en) * 2000-02-08 2010-08-24 Allergan, Inc. Reduced toxicity Clostridial toxin pharmaceutical compositions
US20060269575A1 (en) * 2000-02-08 2006-11-30 Allergan, Inc. Botulinum toxin pharmaceutical compositions formulated with recombinant albumin
US20030118598A1 (en) * 2000-02-08 2003-06-26 Allergan, Inc. Clostridial toxin pharmaceutical compositions
US8632785B2 (en) * 2000-02-08 2014-01-21 Allergan, Inc. Clostridial toxin pharmaceutical composition containing a gelatin fragment
US6805857B2 (en) * 2000-03-06 2004-10-19 Kumarpal A. Shah Method of modulating factor D, factor H and CD4 cell immune response with a polystyrene sulfonate, alginate, and saline infusion solution
US20020106346A1 (en) * 2000-03-06 2002-08-08 Shah Kumarpal A. Immune modulation with polystyrene sulfonate
US6777000B2 (en) * 2001-02-28 2004-08-17 Carrington Laboratories, Inc. In-situ gel formation of pectin
US7494669B2 (en) * 2001-02-28 2009-02-24 Carrington Laboratories, Inc. Delivery of physiological agents with in-situ gels comprising anionic polysaccharides
AU2002366267B2 (en) * 2001-11-19 2007-05-10 Becton, Dickinson And Company Pharmaceutical compositions in particulate form
US20030224000A1 (en) * 2001-12-21 2003-12-04 Kokai-Kun John Fitzgerald Methods for blocking or alleviating staphylococcal nasal colonization by intranasal application of monoclonal antibodies
EP1894591B1 (en) 2002-03-20 2013-06-26 MannKind Corporation Cartridge for an inhalation apparatus
US20030186892A1 (en) * 2002-03-28 2003-10-02 Rajneesh Taneja Enhancement of endogenous gonadotropin production
GB0300531D0 (en) 2003-01-10 2003-02-12 West Pharm Serv Drug Res Ltd Pharmaceutical compositions
EP1638587A4 (en) 2003-02-14 2007-04-18 Univ Missouri RECIPROCAL PROCEDURES AND COMPOSITIONS CONCERNING PROTEASOMAL INTERFERENCE
US7638138B2 (en) 2003-02-21 2009-12-29 Translational Research, Ltd. Compositions for nasal administration of pharmaceuticals
USRE45404E1 (en) 2003-03-27 2015-03-03 Shin Nippon Biomedical Laboratories, Ltd. Powder medicine applicator for nasal cavity
EP1785145A4 (en) * 2004-08-10 2008-08-13 Translational Res Ltd TRANSNASAL COMPOSITION WITH IMMEDIATE EFFECT AND HIGH RESORBIBILITY
DK1786784T3 (da) 2004-08-20 2011-02-14 Mannkind Corp Katalyse af diketopiperazinsyntese
CN104436170B (zh) 2004-08-23 2018-02-23 曼金德公司 用于药物输送的二酮哌嗪盐
US7115561B2 (en) * 2004-09-22 2006-10-03 Patterson James A Medicament composition and method of administration
EP1824450B1 (en) * 2004-10-11 2012-11-14 Nasaleze Patents Limited Compositions for intranasal administration
FR2880272A1 (fr) * 2005-01-04 2006-07-07 Jean Marc Ruiz Preparation contenant des microparticules d'un sel de polymere insoluble portant un principe actif, ainsi que son procede de fabrication
US20090142303A1 (en) * 2005-08-11 2009-06-04 David Edwards Methods and compositions for dried cellular forms
HUE028623T2 (en) 2005-09-14 2016-12-28 Mannkind Corp Active substance formulation method based on increasing the affinity of the active ingredient for binding to the surface of crystalline microparticles
IN2015DN00888A (es) 2006-02-22 2015-07-10 Mannkind Corp
EP2116264B1 (en) * 2006-12-26 2017-09-27 Shin Nippon Biomedical Laboratories, Ltd. Preparation for transnasal application
WO2009039628A1 (en) 2007-09-27 2009-04-02 Immunovaccine Technologies Inc. Use of liposomes in a carrier comprising a continuous hydrophobic phase for delivery of polynucleotides in vivo
WO2009055740A2 (en) 2007-10-24 2009-04-30 Mannkind Corporation Method of preventing adverse effects by glp-1
BRPI0913612B8 (pt) * 2008-06-05 2021-05-25 Immunovaccine Technologies Inc composição injetável de vacina, método para obter a composição e uso da composição
US8485180B2 (en) 2008-06-13 2013-07-16 Mannkind Corporation Dry powder drug delivery system
ES2570400T3 (es) 2008-06-13 2016-05-18 Mannkind Corp Un inhalador de polvo seco y un sistema para el suministro de fármacos
JP5479465B2 (ja) 2008-06-20 2014-04-23 マンカインド コーポレイション 吸入努力をリアルタイムにプロファイルする対話式機器および方法
TWI532497B (zh) 2008-08-11 2016-05-11 曼凱公司 超快起作用胰島素之用途
US8314106B2 (en) 2008-12-29 2012-11-20 Mannkind Corporation Substituted diketopiperazine analogs for use as drug delivery agents
GB0900350D0 (en) * 2009-01-09 2009-02-11 Cambridge Entpr Ltd Formulations of viable bacteria for oral delivery
EP2405963B1 (en) 2009-03-11 2013-11-06 MannKind Corporation Apparatus, system and method for measuring resistance of an inhaler
WO2010131486A1 (en) * 2009-05-15 2010-11-18 Shin Nippon Biomedical Laboratories, Ltd. Intranasal pharmaceutical compositions with improved pharmacokinetics
KR101875969B1 (ko) 2009-06-12 2018-07-06 맨카인드 코포레이션 한정된 비표면적을 갖는 디케토피페라진 마이크로입자
US8827946B2 (en) * 2009-07-31 2014-09-09 Shin Nippon Biomedical Laboratories, Ltd. Intranasal granisetron and nasal applicator
ES2616912T3 (es) 2009-09-16 2017-06-14 Msd Wellcome Trust Hilleman Laboratories Pvt Ltd. Vacuna contra la diarrea debida a E. coli enterotoxigénica (ETEC) y el cólera
JP5784622B2 (ja) 2009-11-03 2015-09-24 マンカインド コーポレ−ション 吸入活動をシミュレートするための装置及び方法
MX359281B (es) 2010-06-21 2018-09-21 Mannkind Corp Sistema y metodos para suministrar un farmaco en polvo seco.
MX353285B (es) 2011-04-01 2018-01-05 Mannkind Corp Paquete de blister para cartuchos farmaceuticos.
WO2012174472A1 (en) 2011-06-17 2012-12-20 Mannkind Corporation High capacity diketopiperazine microparticles
CN103945859A (zh) 2011-10-24 2014-07-23 曼金德公司 用于治疗疼痛的方法和组合物
JP6306523B2 (ja) 2012-03-13 2018-04-04 ベクトン ディキンソン フランス 小型化した薬剤送出部を有する注入器具
WO2014012069A2 (en) 2012-07-12 2014-01-16 Mannkind Corporation Dry powder drug delivery systems and methods
EP2911690A1 (en) 2012-10-26 2015-09-02 MannKind Corporation Inhalable influenza vaccine compositions and methods
AU2014228415B2 (en) 2013-03-15 2018-08-09 Mannkind Corporation Microcrystalline diketopiperazine compositions and methods
KR102321339B1 (ko) 2013-07-18 2021-11-02 맨카인드 코포레이션 열-안정성 건조 분말 약제학적 조성물 및 방법
US11446127B2 (en) 2013-08-05 2022-09-20 Mannkind Corporation Insufflation apparatus and methods
US10307464B2 (en) 2014-03-28 2019-06-04 Mannkind Corporation Use of ultrarapid acting insulin
US10561806B2 (en) 2014-10-02 2020-02-18 Mannkind Corporation Mouthpiece cover for an inhaler
EP3258919B2 (en) * 2015-02-17 2022-11-09 Eli Lilly and Company Nasal powder formulation for treatment of hypoglycemia
CN106362158A (zh) * 2015-07-25 2017-02-01 于杰 增效药物
US11744967B2 (en) 2017-09-26 2023-09-05 Shin Nippon Biomedical Laboratories, Ltd. Intranasal delivery devices
WO2020117080A1 (en) * 2018-12-03 2020-06-11 Uniwersytet Jagielloński A sulfonated polystyrene derivative for use in the treatment and/or prophylaxis of cat flu
EP3698773A1 (en) 2019-02-21 2020-08-26 Università degli Studi di Parma Composition and manufacturing of powders containing nanoadjuvants for mucosal vaccination

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0122036A1 (en) * 1983-03-09 1984-10-17 Teijin Limited Powdery pharmaceutical composition for nasal administration
WO1990009780A1 (en) * 1989-02-25 1990-09-07 Danbiosyst Uk Limited Drug delivery compositions
EP0490806A2 (en) * 1990-09-20 1992-06-17 Sandoz Ltd. Nasal pharmaceutical compositions
EP0588255A1 (en) * 1992-09-12 1994-03-23 Dott Limited Company Physiologically active peptide compositions
WO1994027576A1 (en) * 1993-05-20 1994-12-08 Danbiosyst Uk Limited Nasal drug delivery composition containing nicotine

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS61194034A (ja) * 1985-02-25 1986-08-28 Teijin Ltd 経鼻投与用粉末状組成物
JPS632932A (ja) * 1986-06-23 1988-01-07 Teijin Ltd 経鼻投与用粉末状組成物
JPS63115822A (ja) * 1986-11-04 1988-05-20 Teijin Ltd 生理活性ポリペプチド類の経鼻投与用粉末状組成物
JP2505430B2 (ja) * 1986-11-04 1996-06-12 帝人株式会社 塩基性アミノ酸を含有する経鼻投与用粉末状組成物
US5112804A (en) * 1987-04-01 1992-05-12 Temple University Of The Commonwealth System Of Higher Education Pharmaceutical composition and method of intranasal administration
GB8723846D0 (en) * 1987-10-10 1987-11-11 Danbiosyst Ltd Bioadhesive microsphere drug delivery system
CA1336401C (en) * 1987-10-15 1995-07-25 Brian H. Vickery Intranasal administration of polypeptides in powdered form
US5554388A (en) * 1989-02-25 1996-09-10 Danbiosyst Uk Limited Systemic drug delivery compositions comprising a polycationi substance
US5342922A (en) * 1989-03-08 1994-08-30 Washington University Inhibitors of retroviral protease
US5158761A (en) * 1989-04-05 1992-10-27 Toko Yakuhin Kogyo Kabushiki Kaisha Spray gel base and spray gel preparation using thereof
US5397771A (en) * 1990-05-10 1995-03-14 Bechgaard International Research And Development A/S Pharmaceutical preparation
DK49791D0 (da) * 1991-03-20 1991-03-20 Novo Nordisk As Nasalt pulverpraeparat
WO1993025193A1 (en) * 1992-06-12 1993-12-23 Teijin Limited Pharmaceutical preparation for intra-airway administration
GB9416884D0 (en) * 1994-08-20 1994-10-12 Danbiosyst Uk Drug delivery compositions

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0122036A1 (en) * 1983-03-09 1984-10-17 Teijin Limited Powdery pharmaceutical composition for nasal administration
WO1990009780A1 (en) * 1989-02-25 1990-09-07 Danbiosyst Uk Limited Drug delivery compositions
EP0490806A2 (en) * 1990-09-20 1992-06-17 Sandoz Ltd. Nasal pharmaceutical compositions
EP0588255A1 (en) * 1992-09-12 1994-03-23 Dott Limited Company Physiologically active peptide compositions
WO1994027576A1 (en) * 1993-05-20 1994-12-08 Danbiosyst Uk Limited Nasal drug delivery composition containing nicotine

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2126536A1 (es) * 1996-10-07 1999-03-16 Fuji Yakuhin Kogyo Kk "preparado farmaceutico para administracion intranasal"y procedimiento para su produccion.

Also Published As

Publication number Publication date
AU5945296A (en) 1997-01-23
IT1284049B1 (it) 1998-05-08
ES2116918B1 (es) 1999-04-01
AU702108B2 (en) 1999-02-11
GB2303064B (en) 1999-10-06
CA2180215A1 (en) 1997-01-13
US5942242A (en) 1999-08-24
DE19627392A1 (de) 1997-01-16
KR970005305A (ko) 1997-02-19
FR2736547A1 (fr) 1997-01-17
GB2303064A (en) 1997-02-12
ITMI961261A1 (it) 1997-12-21
CN1140609A (zh) 1997-01-22
ITMI961261A0 (es) 1996-06-21
JPH0925238A (ja) 1997-01-28
JP3098401B2 (ja) 2000-10-16
GB9612841D0 (en) 1996-08-21

Similar Documents

Publication Publication Date Title
ES2116918A1 (es) Medicamento para la administracion nasal.
ZA955892B (en) Formulation for administering by inhalation
MXPA02008403A (es) Mejoras en o relacionadas con el suministro de farmacos por via oral.
NZ508526A (en) Opioid formulations for treating pain
GEP20043260B (en) Aerosolized Active Agent Delivery and Device for Realization Thereof
CA2041579A1 (en) Dosage form
GR900100659A (en) Dosage form for administering oral hupoglycemic glipizide
MY125662A (en) Pharmaceutical formulations containing darifenacin
CA2105165A1 (en) Dosage form for a delayed drug-delivery
WO1994027589A3 (en) Antidepressant dosage form
ATE77947T1 (de) Pentamidin enthaltende pharmazeutische zusammensetzungen.
EP0375628A3 (en) Use of acetyl l-carnitine in the therapeutic treatment of cataract, and pharmaceutical compositions useful in such treatment
PL336658A1 (en) Stabilised tilbone compositions
MY124465A (en) Reduction of infarct volume using citicoline
CA2150183A1 (en) Pharmaceutical composition for the treatment of hemorrhoidal diseases
GR3018930T3 (en) Slow-release medicament containing a dihydropyridine derivate as a nanosol and its preparation.
KR890003399A (ko) 약리적 활성 화합물 및 용도

Legal Events

Date Code Title Description
EC2A Search report published

Date of ref document: 19980716

Kind code of ref document: A1

Effective date: 19980716

PC2A Transfer of patent
FD1A Patent lapsed

Effective date: 20050622